Group 1 - The core viewpoint of the article highlights that SINO PHARMACEUTICAL (02591) experienced a significant decline of over 13% after a two-week cumulative increase of 50% in its stock price [1] - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] - The Shanghai and Shenzhen Stock Exchanges announced that SINO PHARMACEUTICAL will be included in the Hong Kong Stock Connect effective from December 8, 2025, due to adjustments in the Hang Seng Composite MidCap Index [1] Group 2 - SINO PHARMACEUTICAL's self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list on January 1, 2026 [1]
港股异动 银诺医药-B(02591)回吐逾13% 此前两周累计涨幅达50% 今日起正式进入港股通